Quill Science LLC

In addition to these, we are driven by our curiosity and love of learning to support additional therapeutic areas. We make science accessible to elevate its impact. Let's chat!

We're entering a renaissance in neuropsychiatry as we continue learning more about the brain and its workings. Highlights in this month's Quill Quartet include a big approval for schizophrenia, single-cell characterization in neurodegenerative diseases (Alzheimer's, frontotemporal dementia, and supranuclear palsy), new protocols to speed up non-pharmacologic interventions, and investments in new mechanisms of action for investigational drugs to treat severe mental illness. Read more: ❇️ Approval of Cobenfy (KarXT): https://buff.ly/4gGuvqk ❇️ Cross-disorder and disease-specific pathways in dementia: https://buff.ly/3UcxQUk ❇️ New transcranial magnetic stimulation protocol tested: https://buff.ly/4cPESWx ❇️ Biopharma investing in new MOAs: https://buff.ly/4cSJydc And check us out at buff.ly/3RRt4cQ! Do you find the Quill Quartet useful? We will be rolling this into a monthly newsletter soon and would love to know if you'd like this kind of content coming directly to your inbox instead of (or in addition to) possibly appearing in your feed. Let us know! 🙋♂️

I will be on site at Society for Neuroscience #SfN24 TODAY in the exhibitor hall. If you want to meet, send me a DM!

We are excited to announce that Chris of Quill Science LLC has been engaged by a mid-sized medical communications agency to develop a comprehensive scientific communications platform. This collaboration comes at a crucial time as the organization aims to deliver an unparalleled partnership to its clients. The need for additional scientific and communications expertise became evident to execute the development of a scientific platform without overburdening existing staff and causing them to divide their focus. Leveraging our extensive research experience, knowledge of the disease landscape, and strategic scientific storytelling, we will help create consistent language and referencing to support a unified narrative for an investigational new drug. This partnership kicks off this week and will span over three months. By addressing a key pain point for the client, we aim to complete a scientific communications platform that streamlines medical communications to external stakeholders in 2025 for an investigational drug with a novel mechanism of action. We can also offer similar services for your organization. Whether you need evidence and stories to unify and amplify messaging around scientific development or require a singular focus on scientific communications projects, we are here to help.

Happy Labor Day!

Immunotherapy continues to boom in oncology, especially as new forms of adoptive cell therapy are created and tested. Three of our four stories this week are about immunotherapy, and the fourth is about using combination therapy to treat relapsed/refractory B cell lymphoma. Read more: ❇️ Cell therapy in metastatic colorectal cancer (CRC): https://buff.ly/4fBDJUp ❇️ Combination therapy in relapsed DLBCL: https://buff.ly/4dijrxx ❇️ mRNA vaccine against glioblastoma (GBM): https://buff.ly/4fLthti ❇️ First TCR therapy approved in a solid tumor: https://buff.ly/3RXujIx

Does your team have the needed scientific acumen and communications know-how? 💡 Consider using freelance/contract scientific strategy and communications to add to your capabilities. 🔬 Access specialized expertise: Research and communications experience across disciplines can help companies develop, refine, and execute their strategies in product pipeline, marketing, and medical communications. 💵 Save money: The #medcomms industry ebbs and flows, and sometimes you need some extra help with a project or several without onboarding a new full-time employee. Pay for the service you need without paying for downtime. ⏱️ Save time: Experience in the communications business means quick alignment with business goals and strategy to deliver value from the start. Experience in multiple therapeutic areas means it's quick for us to orient with the scientific rationale and clinical development plan. Often, the longest step to getting started is the paperwork, so talk to us before help is desperately needed. 💪 Be more flexible: Working on a project basis allows companies to scale up or down their resources as needed depending on the project's requirements. 📂 Reduce workload for in-house staff: Neuroscience studies show that multitasking is really task-switching, and task-switching is inefficient! Outsourcing scientific strategy and medical writing help to a contract professional can lighten the load for in-house staff, allowing them to focus on their billable work. 🤝 Get quality work: At Quill Science LLC, we are dedicated to advancing science and medicine through top-notch medical strategy and communications consulting. This can help companies ensure that their projects are completed to a high standard, ultimately leading to better outcomes.

Get in touch with us to learn how storytelling can help promote cutting edge science!

It’s #Tech week in Chicago! Connect with Quill Science LLC in person on Thursday 7/25/2024 at TechChicago Day and reception (12–8pm). We're looking forward to meeting you!

Our inaugural issue of The Quill Quartet is here! Four things you might have missed in immunology/rheumatology from the past couple of months. Read more: ▪️Circulating regulatory T cells: https://buff.ly/4f9Qc1i ▪️Digital health in rheumatoid arthritis (RA): https://buff.ly/3W8tgXq ▪️Tyenne approved by the FDA: https://buff.ly/3Wr3Kht ▪️ Long-term safety and efficacy of CAR-T cell treatment in severe and treatment refractory autoimmune disease: https://buff.ly/4fb2LZY More about the CAR-T study: In data presented at EULAR 2024, patients with refractory lupus (SLE n=8), systemic sclerosis (SSc, n=4), and idiopathic inflammatory myositis (IIM=3) were treated with experimental CD19-targeting CAR T cell therapy. At ≥1 year after treatment (median follow-up of 18 months), all 15 patients had stopped immunosuppressive therapy. All patients achieved remission as defined by DORIS remission (SLE), all IIM patients reached ACR/EULAR major response (IIM) and improvement in the EUSTAR activity index (SSc).